Percutaneous Transpedicular Polymethylmethacrylate Vertebroplasty for the Treatment of Spinal Compression Fractures
- 1 November 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 49 (5) , 1105-1115
- https://doi.org/10.1097/00006123-200111000-00017
Abstract
OBJECTIVE: To assess the safety, feasibility, and clinical outcome of percutaneous transpedicular polymethylmethacrylate vertebroplasty (PTPV) for the treatment of spinal compression fractures causing refractory pain. METHODS: We retrospectively reviewed a consecutive group of patients undergoing PTPV at our institution between April 1998 and January 2001. Outcome measures included analgesic requirements, ambulatory status, sleep comfort, and overall quality of life 2 weeks after the procedure. RESULTS: A total of 97 patients (73 women and 24 men) underwent 258 PTPV procedures during 133 treatment sessions. The mean age was 76 years (range, 42–99 yr). The mean duration of follow-up was 14.7 months (range, 2–35 mo). Most of the patients had osteoporotic compression fractures, although some had osteolytic malignancies. Complete follow-up was obtained in 81 patients (84%). Narcotic and analgesic usage decreased in 63% of patients, increased in 7%, and remained the same in 30%. Ambulation and mobility were improved in 51%, worse in 1% and the same in 48%. One-half of the patients were able to sleep more comfortably after the procedure, whereas the other half remained the same. Most patients who reported no change in sleep or ambulation had experienced no impairment of these activities before PTPV. Overall, 74% of patients believed that PTPV significantly enhanced their quality of life and 26% reported no change. No patient was worse after PTPV. One patient with preexisting pneumonia died of respiratory failure after the procedure; another died of an acute stroke weeks later. One patient developed symptomatic pulmonary embolism of cement, and another developed transient quadriceps weakness from radiculopathy. Other complications were minor and infrequent. There were no infections. CONCLUSION: PTPV provided significant relief in a high percentage of patients with refractory pain. PTPV is a safe and feasible treatment for patients with spinal compression fractures.Keywords
This publication has 37 references indexed in Scilit:
- An Ex Vivo Biomechanical Evaluation of an Inflatable Bone Tamp Used in the Treatment of Compression FractureSpine, 2001
- Biomechanical Evaluation of a New Bone Cement for Use in VertebroplastySpine, 2000
- Experimental Vertebroplasty Using Osteoconductive Granular MaterialSpine, 2000
- Percutaneous Vertebroplasty for Pain Relief and Spinal StabilizationSpine, 2000
- The Use of an Injectable, Biodegradable Calcium Phosphate Bone Substitute for the Prophylactic Augmentation of Osteoporotic Vertebrae and the Management of Vertebral Compression FracturesSpine, 1999
- An in vitro biomechanical evaluation of bone cements used in percutaneous vertebroplastyBone, 1999
- Percutaneous vertebroplasty: state of the art.RadioGraphics, 1998
- Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up.Radiology, 1996
- Percutaneous vertebroplasty with acrylic cement in the treatment of a langerhans cell vertebral histiocytosisClinical Rheumatology, 1994
- Population-Based Study of Survival after Osteoporotic FracturesAmerican Journal of Epidemiology, 1993